Plasma 16:0 ceramide as a marker of cardiovascular risk estimated by carotid intima-media thickness in people with type 2 diabetes
Authors' conclusion
Our findings suggest that 16:0 ceramide and the 16:0/24:0 ceramide ratio may serve as plasma biomarkers to improve cardiovascular risk assessment in individuals with T2DM.
Study context
- Population
- Patients with T2D who underwent high-resolution real-time B ultrasonography to measure carotid intima-media thickness (CIMT)
- Participants
- 246 patients
- Outcome
- Association of plasma ceramides with CIMT
Methodological detailslipidomic analysis
- Lipidomic analysis
Main finding
As reported in the abstract
Association with CIMT, adjusted for traditional cardiovascular risk factors
Plasma 16:0 ceramide, standardized β ± SE
0.168 ± 0.072
P = 0.020
16:0/24:0 ceramide ratio, standardized β ± SE
0.180 ± 0.068
P = 0.009
Observational data: associations, not effects.
Further findings
Prediction of CIMT ≥ 0.80 mm
- Plasma 16:0 ceramide, β
- 8.07 ± 3.90 (P = 0.038)
- 16:0/24:0 ceramide ratio, β
- 16.5 ± 7.0 (P = 0.019)
Goodness-of-fit of multivariate models predicting CIMT when added to traditional cardiovascular risk factors
- Plasma 16:0 ceramide, times higher
- 5.7 (P = 0.020)
- 16:0/24:0 ceramide ratio, times higher
- 7.6 (P = 0.015)
Goodness-of-fit of models predicting CIMT ≥ 0.80 mm
- Plasma 16:0 ceramide, fold increase
- 3.1 (P = 0.039)
- 16:0/24:0 ceramide ratio, fold increase
- 10.0 (P = 0.008)
Original publication
Plasma 16:0 ceramide as a marker of cardiovascular risk estimated by carotid intima-media thickness in people with type 2 diabetes. Diabetes Metab. Published 4 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →